Bernard M. Fine

3.6k total citations
39 papers, 2.2k citations indexed

About

Bernard M. Fine is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Bernard M. Fine has authored 39 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Bernard M. Fine's work include HER2/EGFR in Cancer Research (8 papers), Prostate Cancer Treatment and Research (8 papers) and Medical Imaging Techniques and Applications (5 papers). Bernard M. Fine is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Prostate Cancer Treatment and Research (8 papers) and Medical Imaging Techniques and Applications (5 papers). Bernard M. Fine collaborates with scholars based in United States, Australia and Netherlands. Bernard M. Fine's co-authors include Lukas C. Amler, Andrea Pirzkall, Pieter R. Cullis, M. Bloom, Michel Lafleur, Elizabeth A. Punnoose, Siminder Atwal, Mark R. Lackner, Edward Sternin and Rodney J. Hicks and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Physical Review Letters and The Journal of Chemical Physics.

In The Last Decade

Bernard M. Fine

39 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernard M. Fine United States	23	900	891	565	496	343	39	2.2k
Judy Lucas United States	34	2.2k 2.5×	1000 1.1×	393 0.7×	261 0.5×	382 1.1×	69	4.1k
Eddy Pasquier France	32	1.9k 2.1×	1.4k 1.6×	858 1.5×	527 1.1×	102 0.3×	69	4.0k
Charles W. Taylor United States	34	2.4k 2.7×	1.4k 1.6×	430 0.8×	355 0.7×	369 1.1×	82	4.3k
Corbin E. Meacham United States	8	1.3k 1.5×	900 1.0×	716 1.3×	209 0.4×	90 0.3×	10	2.5k
Gadisetti V.R. Chandramouli United States	30	1.6k 1.8×	718 0.8×	847 1.5×	292 0.6×	209 0.6×	75	3.3k
Erina Vlashi United States	25	1.7k 1.9×	1.3k 1.5×	1.0k 1.8×	335 0.7×	308 0.9×	48	3.0k
Enrico Pesenti Italy	28	1.3k 1.5×	1.0k 1.1×	362 0.6×	371 0.7×	250 0.7×	67	2.7k
Daruka Mahadevan United States	34	2.1k 2.4×	1.7k 1.9×	437 0.8×	443 0.9×	123 0.4×	144	4.0k
Jonathan Maybaum United States	34	2.4k 2.7×	1.8k 2.1×	590 1.0×	446 0.9×	187 0.5×	79	3.6k
Mark E. Burkard United States	27	2.5k 2.7×	633 0.7×	427 0.8×	394 0.8×	89 0.3×	124	3.6k

Countries citing papers authored by Bernard M. Fine

Since Specialization

Citations

This map shows the geographic impact of Bernard M. Fine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard M. Fine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard M. Fine more than expected).

Fields of papers citing papers by Bernard M. Fine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard M. Fine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard M. Fine. The network helps show where Bernard M. Fine may publish in the future.

Co-authorship network of co-authors of Bernard M. Fine

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard M. Fine. A scholar is included among the top collaborators of Bernard M. Fine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard M. Fine. Bernard M. Fine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Adam D., Simon J. Harrison, Amrita Krishnan, et al.. (2020). Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Blood. 136(Supplement 1). 42–43. 65 indexed citations

Li, Chunze, Cindy Zhang, Zao Li, et al.. (2019). Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. mAbs. 12(1). 1699768–1699768. 41 indexed citations

Carrasquillo, Jorge A., Bernard M. Fine, Neeta Pandit‐Taskar, et al.. (2019). Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of Nuclear Medicine. 60(11). 1517–1523. 42 indexed citations

Kågedal, Matts, Divya Samineni, William R. Gillespie, et al.. (2019). Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates. CPT Pharmacometrics & Systems Pharmacology. 8(8). 606–615. 12 indexed citations

Kågedal, Matts, Leonid Gibiansky, Jian Xu, et al.. (2017). Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates. Journal of Pharmacokinetics and Pharmacodynamics. 44(6). 537–548. 9 indexed citations

Stagg, Nicola J., Ben‐Quan Shen, Flávia Brunstein, et al.. (2016). Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic. Regulatory Toxicology and Pharmacology. 82. 1–13. 34 indexed citations

Lamberts, Laetitia E., C. Willemien Menke‐van der Houven van Oordt, Frederike Bensch, et al.. (2015). ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment. Clinical Cancer Research. 22(7). 1642–1652. 77 indexed citations

Danila, Daniel C., Howard I. Scher, Edith Szafer‐Glusman, et al.. (2015). Abstract 4310: Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 75(15_Supplement). 4310–4310. 1 indexed citations

Danila, Daniel C., Martin Fleisher, Jorge A. Carrasquillo, et al.. (2015). STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 33(15_suppl). 5029–5029. 4 indexed citations

10.

Hughes, Brett, Linda Mileshkin, P. Townley, et al.. (2014). Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. The Oncologist. 19(2). 175–176. 19 indexed citations

11.

Punnoose, Elizabeth A., Siminder Atwal, Weiqun Liu, et al.. (2012). Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib. Clinical Cancer Research. 18(8). 2391–2401. 341 indexed citations

12.

Mileshkin, Linda, Rodney J. Hicks, Brett Hughes, et al.. (2011). Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib. Clinical Cancer Research. 17(10). 3304–3315. 106 indexed citations

13.

Binns, David, Andrea Pirzkall, Wei Yu, et al.. (2011). Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 38(4). 642–650. 26 indexed citations

14.

Kaiser, Lee D., et al.. (2011). Decision Making for a Companion Diagnostic in an Oncology Clinical Development Program. Drug Information Journal. 45(5). 645–655. 4 indexed citations

15.

Duenwald, Sven, Mingjie Zhou, Yanqun Wang, et al.. (2009). Development of a microarray platform for FFPET profiling: application to the classification of human tumors. Journal of Translational Medicine. 7(1). 65–65. 14 indexed citations

16.

Dai, Hongyue, Laura van’t Veer, John R. Lamb, et al.. (2005). A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients. Cancer Research. 65(10). 4059–4066. 207 indexed citations

17.

Fine, Bernard M., Jayanti Pande, Aleksey Lomakin, Olutayo Ogun, & George B. Benedek. (1995). Dynamic Critical Phenomena in Aqueous Protein Solutions. Physical Review Letters. 74(1). 198–201. 31 indexed citations

18.

Lafleur, Michel, Pieter R. Cullis, Bernard M. Fine, & M. Bloom. (1990). Comparison of the orientational order of lipid chains in the L.alpha. and HII phases. Biochemistry. 29(36). 8325–8333. 48 indexed citations

19.

Lafleur, Michel, Bernard M. Fine, Edward Sternin, Pieter R. Cullis, & M. Bloom. (1989). Smoothed orientational order profile of lipid bilayers by 2H-nuclear magnetic resonance. Biophysical Journal. 56(5). 1037–1041. 212 indexed citations

20.

Sternin, Edward, et al.. (1988). Acyl chain orientational order in the hexagonal HII phase of phospholipid-water dispersions. Biophysical Journal. 54(4). 689–694. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact